Cargando…

Increasing incidence and antimicrobial resistance in Escherichia coli bloodstream infections: a multinational population-based cohort study

BACKGROUND: Escherichia coli is an important pathogen in humans and is the most common cause of bacterial bloodstream infections (BSIs). The objectives of our study were to determine factors associated with E. coli BSI incidence rate and third-generation cephalosporin resistance in a multinational p...

Descripción completa

Detalles Bibliográficos
Autores principales: MacKinnon, Melissa C., McEwen, Scott A., Pearl, David L., Lyytikäinen, Outi, Jacobsson, Gunnar, Collignon, Peter, Gregson, Daniel B., Valiquette, Louis, Laupland, Kevin B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422618/
https://www.ncbi.nlm.nih.gov/pubmed/34488891
http://dx.doi.org/10.1186/s13756-021-00999-4
_version_ 1783749311091179520
author MacKinnon, Melissa C.
McEwen, Scott A.
Pearl, David L.
Lyytikäinen, Outi
Jacobsson, Gunnar
Collignon, Peter
Gregson, Daniel B.
Valiquette, Louis
Laupland, Kevin B.
author_facet MacKinnon, Melissa C.
McEwen, Scott A.
Pearl, David L.
Lyytikäinen, Outi
Jacobsson, Gunnar
Collignon, Peter
Gregson, Daniel B.
Valiquette, Louis
Laupland, Kevin B.
author_sort MacKinnon, Melissa C.
collection PubMed
description BACKGROUND: Escherichia coli is an important pathogen in humans and is the most common cause of bacterial bloodstream infections (BSIs). The objectives of our study were to determine factors associated with E. coli BSI incidence rate and third-generation cephalosporin resistance in a multinational population-based cohort. METHODS: We included all incident E. coli BSIs (2014–2018) from national (Finland) and regional (Australia [Canberra], Sweden [Skaraborg], and Canada [Calgary, Sherbrooke, and western interior]) surveillance. Incidence rates were directly age and sex standardized to the European Union 28-country 2018 population. Multivariable negative binomial and logistic regression models estimated factors significantly associated with E. coli BSI incidence rate and third-generation cephalosporin resistance, respectively. The explanatory variables considered for inclusion in both models were year (2014–2018), region (six areas), age (< 70-years-old and ≥ 70-years-old), and sex (female and male). RESULTS: We identified 31,889 E. coli BSIs from 40.7 million person-years of surveillance. Overall and third-generation cephalosporin-resistant standardized rates were 87.1 and 6.6 cases/100,000 person-years, respectively, and increased 14.0% and 40.1% over the five-year study. Overall, 7.8% (2483/31889) of E. coli BSIs were third-generation cephalosporin-resistant. Calgary, Canberra, Sherbrooke, and western interior had significantly lower E. coli BSI rates compared to Finland. The significant association between age and E. coli BSI rate varied with sex. Calgary, Canberra, and western interior had significantly greater odds of third-generation cephalosporin-resistant E. coli BSIs compared to Finland. Compared to 2014, the odds of third-generation cephalosporin-resistant E. coli BSIs were significantly increased in 2016, 2017, and 2018. The significant association between age and the odds of having a third-generation cephalosporin-resistant E. coli BSI varied with sex. CONCLUSIONS: Increases in overall and third-generation cephalosporin-resistant standardized E. coli BSI rates were clinically important. Overall, E. coli BSI incidence rates were 40–104% greater than previous investigations from the same study areas. Region, sex, and age are important variables when analyzing E. coli BSI rates and third-generation cephalosporin resistance in E. coli BSIs. Considering E. coli is the most common cause of BSIs, this increasing burden and evolving third-generation cephalosporin resistance will have an important impact on human health, especially in aging populations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13756-021-00999-4.
format Online
Article
Text
id pubmed-8422618
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84226182021-09-09 Increasing incidence and antimicrobial resistance in Escherichia coli bloodstream infections: a multinational population-based cohort study MacKinnon, Melissa C. McEwen, Scott A. Pearl, David L. Lyytikäinen, Outi Jacobsson, Gunnar Collignon, Peter Gregson, Daniel B. Valiquette, Louis Laupland, Kevin B. Antimicrob Resist Infect Control Research BACKGROUND: Escherichia coli is an important pathogen in humans and is the most common cause of bacterial bloodstream infections (BSIs). The objectives of our study were to determine factors associated with E. coli BSI incidence rate and third-generation cephalosporin resistance in a multinational population-based cohort. METHODS: We included all incident E. coli BSIs (2014–2018) from national (Finland) and regional (Australia [Canberra], Sweden [Skaraborg], and Canada [Calgary, Sherbrooke, and western interior]) surveillance. Incidence rates were directly age and sex standardized to the European Union 28-country 2018 population. Multivariable negative binomial and logistic regression models estimated factors significantly associated with E. coli BSI incidence rate and third-generation cephalosporin resistance, respectively. The explanatory variables considered for inclusion in both models were year (2014–2018), region (six areas), age (< 70-years-old and ≥ 70-years-old), and sex (female and male). RESULTS: We identified 31,889 E. coli BSIs from 40.7 million person-years of surveillance. Overall and third-generation cephalosporin-resistant standardized rates were 87.1 and 6.6 cases/100,000 person-years, respectively, and increased 14.0% and 40.1% over the five-year study. Overall, 7.8% (2483/31889) of E. coli BSIs were third-generation cephalosporin-resistant. Calgary, Canberra, Sherbrooke, and western interior had significantly lower E. coli BSI rates compared to Finland. The significant association between age and E. coli BSI rate varied with sex. Calgary, Canberra, and western interior had significantly greater odds of third-generation cephalosporin-resistant E. coli BSIs compared to Finland. Compared to 2014, the odds of third-generation cephalosporin-resistant E. coli BSIs were significantly increased in 2016, 2017, and 2018. The significant association between age and the odds of having a third-generation cephalosporin-resistant E. coli BSI varied with sex. CONCLUSIONS: Increases in overall and third-generation cephalosporin-resistant standardized E. coli BSI rates were clinically important. Overall, E. coli BSI incidence rates were 40–104% greater than previous investigations from the same study areas. Region, sex, and age are important variables when analyzing E. coli BSI rates and third-generation cephalosporin resistance in E. coli BSIs. Considering E. coli is the most common cause of BSIs, this increasing burden and evolving third-generation cephalosporin resistance will have an important impact on human health, especially in aging populations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13756-021-00999-4. BioMed Central 2021-09-06 /pmc/articles/PMC8422618/ /pubmed/34488891 http://dx.doi.org/10.1186/s13756-021-00999-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
MacKinnon, Melissa C.
McEwen, Scott A.
Pearl, David L.
Lyytikäinen, Outi
Jacobsson, Gunnar
Collignon, Peter
Gregson, Daniel B.
Valiquette, Louis
Laupland, Kevin B.
Increasing incidence and antimicrobial resistance in Escherichia coli bloodstream infections: a multinational population-based cohort study
title Increasing incidence and antimicrobial resistance in Escherichia coli bloodstream infections: a multinational population-based cohort study
title_full Increasing incidence and antimicrobial resistance in Escherichia coli bloodstream infections: a multinational population-based cohort study
title_fullStr Increasing incidence and antimicrobial resistance in Escherichia coli bloodstream infections: a multinational population-based cohort study
title_full_unstemmed Increasing incidence and antimicrobial resistance in Escherichia coli bloodstream infections: a multinational population-based cohort study
title_short Increasing incidence and antimicrobial resistance in Escherichia coli bloodstream infections: a multinational population-based cohort study
title_sort increasing incidence and antimicrobial resistance in escherichia coli bloodstream infections: a multinational population-based cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422618/
https://www.ncbi.nlm.nih.gov/pubmed/34488891
http://dx.doi.org/10.1186/s13756-021-00999-4
work_keys_str_mv AT mackinnonmelissac increasingincidenceandantimicrobialresistanceinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT mcewenscotta increasingincidenceandantimicrobialresistanceinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT pearldavidl increasingincidenceandantimicrobialresistanceinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT lyytikainenouti increasingincidenceandantimicrobialresistanceinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT jacobssongunnar increasingincidenceandantimicrobialresistanceinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT collignonpeter increasingincidenceandantimicrobialresistanceinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT gregsondanielb increasingincidenceandantimicrobialresistanceinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT valiquettelouis increasingincidenceandantimicrobialresistanceinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy
AT lauplandkevinb increasingincidenceandantimicrobialresistanceinescherichiacolibloodstreaminfectionsamultinationalpopulationbasedcohortstudy